NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the NasopharynxStage IVA Verrucous Carcinoma of the LarynxStage IVB Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the HypopharynxStage IVA Salivary Gland Cancer
- Interventions
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00507767
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: CTLA-4 IgOther: Placebo
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2020-05-06
- Target Recruit Count
- 112
- Registration Number
- NCT00505375
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
🇺🇸Stanford University, Stanford, California, United States
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00504153
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Adult Solid NeoplasmClear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Other: Computed TomographyOther: Fluorothymidine F-18Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Positron Emission Tomography
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00499135
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1
Completed
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Burkitt Lymphoma
- Interventions
- Other: pharmacological study
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00499811
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Phase 3
Terminated
- Conditions
- Recurrent Rectal CancerStage IVB Colon CancerStage IVA Rectal CancerStage IVB Rectal CancerRecurrent Colon CancerStage IVA Colon Cancer
- Interventions
- Biological: cetuximabBiological: bevacizumab
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00499369
- Locations
- 🇺🇸
Saint Edward Mercy Medical Center, Ft. Smith, Arkansas, United States
🇺🇸Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
🇺🇸East Bay Radiation Oncology Center, Castro Valley, California, United States
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Phase 2
Completed
- Conditions
- Adult Anaplastic AstrocytomaAdult Giant Cell GlioblastomaAdult Mixed GliomaAdult GliosarcomaAdult Diffuse AstrocytomaAdult GlioblastomaAdult OligodendrogliomaAdult Pineal Gland Astrocytoma
- Interventions
- Other: pharmacological study
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00499473
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Phase 2
Completed
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic MeningiomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Central Nervous System Germ Cell TumorAdult Choroid Plexus TumorAdult Diffuse AstrocytomaAdult EpendymomaAdult Grade II Meningioma
- Interventions
- Drug: placeboProcedure: magnetic resonance imagingProcedure: quality-of-life assessment
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT00492089
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological studyOther: high performance liquid chromatographyGenetic: microarray analysisGenetic: RNA analysisOther: mass spectrometryGenetic: DNA methylation analysisOther: matrix-assisted laser desorption/ionization time of flight mass spectrometry
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00492401
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
Completed
- Conditions
- Tobacco AddictionHIV InfectionsAIDSLung CancerDrug Addiction
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00491335
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States